Founded in 2015, Shenzhen Sibionics Technology Co., Ltd. is committed to R&D and industrialization of innovative medical devices in the field of chronic disease management, and has more than 500 employees. The core team is led by science and engineering scientists from Tsinghua University, Peking University, California Institute of Technology, Princeton University, University of Washington and other prestigious universities. The main projects include continuous glucose monitoring (CGM), AI fundus screening, artificial retina, capsule gastroscopy robot, etc., breaking the foreign technology monopoly in multiple segments and leading the development of fundamental disciplines and industry technology. It has undertaken and participated in 3 key R&D projects of the Ministry of Science and Technology, and has become a quasi-unicorn enterprise in the field of innovative medical devices in China.